Background and Purpose-Deciphering whether a transient neurological event (TNE) is of ischemic or nonischemic etiology can be challenging. Ischemia of cerebral tissue elicits an immune response in stroke and transient ischemic attack (TIA). This response, as detected by RNA expressed in immune cells, could potentially distinguish ischemic from nonischemic TNE. Methods-Analysis of 208 TIAs, ischemic strokes, controls, and TNE was performed. RNA from blood was processed on microarrays. TIAs (nϭ26) and ischemic strokes (nϭ94) were compared with controls (nϭ44) to identify differentially expressed genes (false discovery rate Ͻ0.05, fold change Ն1.2). Genes common to TIA and stroke were used predict ischemia in TIA diffusion-weighted imaging-positive/minor stroke (nϭ17), nonischemic TNE (nϭ13), and TNE of unclear etiology (nϭ14). Results-Seventy-four genes expressed in TIA were common to those in ischemic stroke. Functional pathways common to TIA and stroke related to activation of innate and adaptive immune systems, involving granulocytes and B cells. A prediction model using 26 of the 74 ischemia genes distinguished TIA and stroke subjects from control subjects with 89% sensitivity and specificity. In the validation cohort, 17 of 17 TIA diffusion-weighted imaging-positive/minor strokes were predicted to be ischemic, and 10 of 13 nonischemic TNE were predicted to be nonischemic. In TNE of unclear etiology, 71% were predicted to be ischemic. These subjects had higher ABCD 2 scores. Conclusions-A common molecular response to ischemia in TIA and stroke was identified, relating to activation of innate and adaptive immune systems. TNE of ischemic etiology was identified based on gene profiles that may be of clinical use once validated. (Stroke. 2012;43:1006-1012.)
S
ystemic inflammation is linked to ischemic stroke and transient ischemic attack (TIA). Cerebral ischemia produces many endogenous ligands and cytokines that elicit an immune response. 1 Leukocytes, including neutrophils and monocytes, are activated and recruited to initiate processes of containment, removal, and repair. We have previously demonstrated in a rat model of TIA that a peripheral immune response occurs to transient brain ischemia with similarities to that observed in experimental brain infarction. 2, 3 This suggests that aspects of the immune response to cerebral ischemia in TIA and stroke are common and may be useful in identifying ischemic events.
In clinical practice, deciphering whether a transient neurological event (TNE) is of ischemic or nonischemic etiology is often difficult. Many common neurological conditions mimic the symptoms of TIA, including migraine, seizure, and syncope. The transient nature of TIA adds to the diagnostic challenge because objective deficits generally resolve by the time of presentation and assessment of symptoms is reliant on patient recall and physician interpretation. Current diagnostic tests including neuroimaging, electrocardiogram, and electroencephalogram are frequently unremarkable, leaving the cause of a TNE unclear. As a result, TIA is estimated to be incorrectly diagnosed in as many as 50% of cases. 4 -8 However, correctly identifying ischemic TNE is critical because the risk for stroke is high in TIA and can be reduced by early initiation of stroke prevention therapy. 9 Additionally, identifying nonischemic TNE (which has a very low risk of stroke) will improve risk stratification and use of healthcare resources. Thus, improved methods to distinguish ischemic from nonischemic causes of TNE are needed.
We hypothesized that the common immune response to ischemia in TIA and stroke could distinguish ischemic from nonischemic TNE. Previous studies have demonstrated an immune response in patients with stroke by evaluating leukocyte RNA expression using whole genome microarrays. 10 -12 However, the distinction between immune response to cerebral ischemia and cerebral infarction remains unclear. We report the pathways associated with the peripheral immune response to cerebral ischemia, which with further study and validation may have clinical use to identify ischemic causes of TNE.
Subjects and Methods

Study Patients
Patients with ischemic stroke, TIA, and control subjects were enrolled from the University of California Davis and the University of California San Francisco. Study protocols were approved by the Institutional Review Boards at each site and written informed consent was obtained from each patient. All patients received standardized clinical evaluations, including medical history, brain imaging, Doppler, vascular angiography, electrocardiogram, echocardiogram, and 24-to 48-hour cardiac monitoring. Blood samples were drawn into PAXgene tubes (PreAnalytiX, Hilden, Germany) within 72 hours of symptom onset for gene expression analysis.
The diagnoses of stroke, TIA, and TNE of nonischemic etiology required consensus of 3 study neurologists. Subjects where a consensus was not obtained were classified as TNE of unclear etiology. A derivation cohort of TIA (nϭ26), ischemic stroke (nϭ94), and matched vascular risk factor controls (nϭ44) were used to identify genes associated with cerebral ischemia ( Figure 1 ; Table 1 ). TIA was defined as an episode of neurological dysfunction lasting Յ24 hours resulting from focal cerebral ischemia with no restricted diffusion on MRI. Ischemic stroke was defined by neurological deficits persisting Ͼ24 hours with acute cerebral infarction on imaging. Patients with intracerebral hemorrhage or hemorrhagic infarction were excluded from study. Stroke subtype was classified as large-artery atherosclerotic, cardioembolic, small-vessel lacunar, and cryptogenic as previously described. 13 Controls were subjects with vascular risk factors without symptomatic cardiovascular disease (stroke, myocardial infarction, peripheral vascular disease) who were similar in age, race, and gender to TIA and stroke subjects. Differences between groups were analyzed using Fisher exact test, 2-tailed t test, or Wilcoxon-Mann-Whitney test where appropriate (Stata 10.1, College Station, TX).
The genes associated with cerebral ischemia were evaluated in a validation cohort comprised of ischemic TNE (nϭ17) and nonischemic TNE (nϭ13; Supplemental Table I ; http://stroke.ahajournals.org). Ischemic TNE were patients with transient neurological symptoms with diffusion-weighted-positive MRI and minor strokes with a National Institutes of Health Stroke Scale score Յ5 at 24 hours. Nonischemic TNE included patients with migraine, seizure, or Figure 1 . Flow diagram of study analyses. A, To derive common ischemia genes, TIA and ischemic stroke subjects were compared with control subjects. Of the 160 probesets differentially expressed in TIA, 74 (46%) were identical to those in ischemic stroke (FDR Ͻ0.05, fold change Ն1.2). A subset of 26 probe sets were found to optimally distinguish TIA and ischemic stroke from controls using LDA. B, A prediction model using these 26 probe sets was developed and evaluated by crossvalidation on the original validation cohort and on a validation cohort of TNE of known ischemic and nonischemic etiology. C, The 26 probe sets were subsequently used to predict ischemia in TNE of unclear etiology. TIA indicates transient ischemic attack; FDR, false discovery rate; LDA, linear discriminant analysis; TNE, transient neurological event. Genes associated with cerebral ischemia were used predict ischemia in TNE of unclear etiology (nϭ14; Figure 1 ). TNE of unclear etiology were patients with a transient neurological event in which diagnostic consensus was not obtained among the 3 study neurologists and included 2 subjects in which TIA was thought to be the cause but a brain MRI was not available for review.
Sample Processing
A venous blood sample was collected in PAXgene tubes within 72 hours of stroke or TIA onset (PreAnalytiX). Samples were stored at Ϫ80°C and processed at the same time in the same laboratory to reduce batch effect. Total RNA was isolated according to the manufacturer's protocol (PAXgene blood RNA kit; Pre-AnalytiX). RNA concentration was determined by Nano-Drop (Thermo Fisher) and RNA quality by an Agilent 2100 Bioanalyzer. Samples required A 260 /A 280 absorbance ratios of purified RNA Ն2.0 and 28S/18S rRNA ratios Ն1.8. NuGENЈs Ovation Whole Blood Solution (Nu-GEN Technologies, San Carlos, CA) was used for reverse transcription, amplification, and sample labeling. Hybridization of each RNA sample was performed according to the manufacturer's protocol on Affymetrix Human U133 Plus 2.0 GeneChips (Affymetrix, Santa Clara, CA). Arrays were washed and processed on a Fluidics Station 450 and scanned on a GeneChip Scanner 3000. Samples were randomly assigned to microarray batch stratified by diagnosis.
Microarray Data Analysis
Microarray data files were preprocessed using robust multichip averaging, mean-centering standardization, and log2 transformation (Partek Genomics Suite 6.4; Partek Inc, St Louis, MO). Nonspecific probe sets with an interquartile range Ͻ0.5 across the all subjects were filtered as previously described. 14, 15 Patients with TIA and ischemic stroke were compared with control subjects using analysis of covariance adjusted for age and batch. The analyses included TIA versus control subjects and ischemic stroke versus control subjects. After Benjamini-Hochberg false discovery rate correction for multiple comparisons, probe sets with a corrected P-value Ͻ0.05 and fold change Ն1.2 were considered significant.
Gene Functional Analysis
To identify functional pathways associated with the differentially expressed genes, Ingenuity Pathway Analysis (Ingenuity Systems, www.ingenuity.com) was used. Pathways with a greater number of genes than expected by chance were considered significant (PϽ0.05, Fisher exact test). To identify genes associated with specific immune cells, the list of differentially expressed genes for TIA and stroke were overlapped with previously published lists of genes shown to be unique to granulocytes, natural killer cells, monocytes, B cells, CD4 T cells, and CD8 T cells. 16 
Prediction Analysis
The probe sets common to ischemic stroke and TIA were used to develop a prediction model to discriminate ischemia from control subjects (Figure 1 ). This control group was used to identify genes due to ischemia and not due to vascular risk factors. From the list of 74 common ischemia genes, the optimal genes to discriminate ischemia from control subjects were identified using forward selection linear discriminant analysis (LDA). LDA is an analytic method that identifies a linear combination of features to separate Ն2 classes. For this analysis, the genes expressed in blood were the features, and the classes were ischemia and nonischemia. A panel of 26 genes was identified and used to develop an LDA prediction model to distinguish ischemia from control subjects. This model was evaluated using 10-fold leave-1-out cross-validation analysis and in a second cohort of subjects with TIA diffusion-weighted imagingpositive/minor stroke (nϭ17) and nonischemic TNE (nϭ13: migraine nϭ7; seizure nϭ3; syncope nϭ3; Figure 1 ). The developed model was then used to predict TNE of unclear etiology.
Results
Demographic and clinical characteristics of subjects analyzed in the derivation set are shown in Table 1 . There were 26 subjects with TIA, 94 with ischemic stroke, and 44 control subjects. The mean age was 64.1 years (Ϯ11.0 SD) and 49.3% were male. The cohort was ethnically diverse: 105 (64%) were white, 28 (17%) were black, 16 (10%) were Hispanic, 10 (6%) were Asian, and 5 (3%) were of other race. TIA subjects had a mean ABCD 2 score of 4.6 (range, 2-6). Control subjects had vascular risk factors but no symptomatic cerebrovascular or cardiovascular disease. Age, gender, race, hypertension, diabetes, and hyperlipidemia were not significantly different between TIA or ischemic stroke and control subjects.
A total of 160 annotated probe sets representing 145 genes were significantly different between TIA and control subjects (false discovery rate Ͻ0.05 fold change Ն1.2). A total of 461 annotated probe sets representing 413 genes were significantly different between ischemic stroke and control subjects (false discovery rate Ͻ0.05 fold change Ն1.2). There were 74 probe sets (46%) of the 160 probe sets differentially expressed in TIA that were common to the 461 probe sets differentially expressed in ischemic stroke ( Figure 1 ). Analysis of the common functional pathways between TIA and ischemic stroke are shown in Table 2 . Of the common genes and pathways in TIA and stroke, most were associated with activation and development of the immune cells, including Toll-like receptor (TLR) 5, TLR6, TLR10, caspase-1, caspase-6, caspase-recruitment domain protein 16, interleukin-8, interleukin-10, CD36, and CD86. Triggering receptor expressed on myeloid cell 1 signaling involving Toll-like receptor was the top canonical pathway common in TIA and stroke (Table 2 ). There were 86 probe sets unique to TIA (Supplemental Table III ), the functional analyses of which are shown in Supplemental Table IV. Using genes previously identified as unique to each immune cell type, 16 the proportion of cell types expressing RNA in TIA and ischemic stroke were estimated. Genes differentially expressed in TIA were associated with granulocytes and B cells ( Figure 2 ). Genes differentially expressed in ischemic stroke were associated with granulocytes, monocytes, natural killer cells and B cells, and, to a lesser extent, with megakaryocytes and CD4 T cells ( Figure 2 ).
Of the 74 probe sets (63 genes) common to TIA and stroke, a 26-gene panel was identified that optimally distinguished subjects with cerebral ischemia from control subjects ( Figure  1 ). An LDA model based on this gene panel correctly predicted 26 of 26 TIA subjects, 85 of 94 ischemic stroke subjects, and 41 of 44 control subjects. On crossvalidation analysis, the 26-gene LDA model correctly predicted 89% of cerebral ischemia subjects and 89% of control subjects ( Figure 3 ). The probability of predicted diagnosis for the majority of subjects with and without ischemia was Ͼ90%.
In a validation cohort of TIAs with diffusion-weighted imaging-positive lesions and minor strokes, ischemia was the predicted diagnosis in 17 of 17 subjects (100%). In a cohort of nonischemic TNE that included patients with migraine, seizure, and syncope, nonischemia was predicted in 10 of 13 subjects (77%). The 26-gene LDA model was then used to predict ischemia in subjects with TNE of unclear etiology. Cerebral ischemia was predicted in 71% (nϭ10) of subjects, and 29% (nϭ4) were predicted to be nonischemic events. Although the sample size was small, TNE of unclear etiology predicted to be ischemic had higher ABCD 2 scores compared with those predicted to be nonischemic (Table 3) .
Discussion
TIA and stroke were demonstrated to share a common immune response to cerebral ischemia. Half of the genes expressed in TIA were also expressed in stroke, representing activation of innate and adaptive immune responses. This common immune response to ischemia in TIA and stroke was able to distinguish subjects with and without cerebral ischemia. Given the difficulty in determining etiology of TNE, and the significance of this distinction to treatment, a reliable marker that identifies ischemic TNE would be clinically useful.
Immune Response to Ischemia to Identify TIA
TIA is a challenging diagnosis because transient neurological symptoms can be mimicked by several common conditions, including migraine, seizure, and syncope. 4,6 -8 The genes associated with cerebral ischemia, as identified by those common to TIA and ischemic stroke, might identify cerebral ischemia in patients with transient neurological symptoms. We identified a profile of 26 genes able to distinguish TIA and minor stroke subjects from nonischemic TNE. When the profile was used to predict subjects with transient neurological symptoms of unclear etiology, 71% were predicted to be ischemic. This is important because improved recognition of ischemic TNE could improve the delivery of urgent neurovascular evaluation and treatment shown to prevent stroke in TIA. Furthermore, identifying nonischemic TNE that mimics Proportional representation of the immune cells that contributed to RNA expression in blood in patients with TIA and ischemic stroke. Previous studies have identified genes unique to each cell type in blood. 16 These profiles were used to identify cells contributing to the differentially expressed genes in TIA and stroke. The genes differentially expressed in TIA were associated mostly with granulocytes and B cells. The genes differentially expressed in ischemic stroke were associated mostly with granulocytes, monocytes, natural killer cells, and B cells with some contribution from megakaryocytes and CD4 T cells. TIA indicates transient ischemic attack.
TIA could reduce the costs of hospital observation and extensive evaluation typical of patients diagnosed with TIA.
TNE predicted to be ischemic tended to have higher ABCD 2 scores. This is consistent with other studies demonstrating the diagnostic potential of the ABCD 2 score to identify transient events due to ischemia. 17, 18 An ABCD 2 score Ն4 has been shown to identify 60% of TIAs and 82% of minor strokes. 18 Additionally, an ABCD 2 score Ͻ4 identified 65% of nonischemic TNE. However, this leaves 40% of TIAs, 18% of minor strokes, and 35% of nonischemic TNE incorrectly identified, indicating that additional methods to distinguish ischemic from nonischemic TNE are required. Diagnosis is critical because early stroke risk is low in nonischemic TNE and is as high as 10% to 25% in TIA. 19 The genes identified in this study were able to identify all TIAs and minor ischemic strokes, including those subjects with an ABCD 2 score Ͻ4. Further study is required to determine if an RNA profile can add to the ABCD2 and/or diffusionweighted MRI. The ABCD 2 score and/or RNA may be of use in patients in whom MRI cannot be performed due to contraindications, cost, or accessibility. Additionally, RNA may provide additional information that complements the ABCD 2 score in TIA. For example, patients with a low ABCD 2 score with an RNA profile suggesting ischemia may benefit from urgent evaluation. However, this requires additional evaluation.
Immune Response Common to TIA and Stroke
The common peripheral immune response to cerebral ischemia identified was associated with communication between innate and adaptive immune cells, including activation of granulocytes and B cells. This response reflects features shared by TIA and stroke, including immune cell interaction with ischemic but not infarcted tissue, acute thrombosis, and possibly a stress response to acute injury.
Aspects of the common immune response have previously been demonstrated in stroke. 20 TLR signaling was present in both TIA and stroke, with expression of TLR5, TLR6, and TLR10 identified. TLRs play critical roles in initiating the innate immune response and shaping the adaptive immune response. In mice, knockout of TLR4 results in smaller infarct volumes, better outcomes, and decreased inflammatory markers including interferon regulatory factor-1, inducible nitric oxide synthase, cyclo-oxygenase-2, and matrix metalloproteinase-9. 21, 22 Likewise, knockout of TLR2 can reduce central nervous system inflammatory markers inter- Figure 3 . Probability plots of the predicted diagnosis of cerebral ischemia in TIA and ischemic stroke versus control subjects. The predicted probabilities are from crossvalidation of the LDA 26 common ischemic gene model on the derivation cohort. The predicted probability of ischemia versus nonischemia in shown for (A) the 26 patients clinically diagnosed as TIA; (B) the 94 with ischemic strokes; and (C) the 44 vascular risk factor control subjects. The probability of a subject being ischemia is shown by white boxes, and the probability of a subject being nonischemia is shown by grey diamonds. Cerebral ischemia was correctly predicted in 89% of subjects, and nonischemia was correctly predicted in 89% of control subjects. The probability of predicted diagnosis for the majority of subjects was Ͼ90%. TIA indicates transient ischemic attack; LDA, linear discriminant analysis. 25 In human stroke, TLR expression is less well characterized. The expression of TLR2 and TLR4 on monocytes at the time of stroke is associated with larger infarct volumes, increased protein levels of interleukin-1B, tumor necrosis factor-␣, interleukin-6, and vascular cell adhesion molecule-1, and worse outcomes at 3 months. 26, 27 TLR7 and TLR8 may also be associated with poor outcome and greater inflammatory response. 28 Our study suggests that TLR5, 6, and 10 play a role in the peripheral inflammatory response in both stroke and TIA, suggesting that further study of these receptors is required.
Triggering receptor expressed on myeloid cell 1 (TREM-1) signaling was the top common pathway identified in both TIA and ischemic stroke. TREM is a receptor that can modulate the innate immune response to prevent excessive inflammation and tissue damage. 29, 30 TREM regulation of TLR responses is mediated through modification of the caspase-recruitment domain protein complex. 31, 32 In our study, expression of TLR and caspase-recruitment domain protein genes was identified with caspase-recruitment domain protein 16 being expressed more in TIA than stroke. Further study of TREM-1 signaling in cerebral ischemia may provide a means to modulate inflammation in ischemic brain injury.
The expression of genes associated with B cells occurred in both stroke and TIA. This suggests that B cells may play an important role in cerebral ischemia. B cells have prominent effects on inflammatory responses. 21, 33 Depletion of B cells in multiple sclerosis worsens central nervous system injury. 34, 35 In experimental stroke, infarct size can be reduced with B cell transfusion. 36 The ability of B cells to limit central nervous system injury is dependent on the anti-inflammatory effects of interleukin-10. 36 -38 Our study suggests that B cells are important in the immune response to cerebral ischemia in stroke and TIA.
Limitations
Sample size was small in this preliminary study. Larger studies are required to ensure TIA and nonischemic TNE populations are comprehensively evaluated. Microarray studies evaluating many genes have an inherent risk of false discovery. Although we adjusted for this risk using false discovery rate-corrected probability values and assessed the developed model in a validation cohort, evaluation of identified genes and pathways in a second independent cohort is required. Reliability of findings is increased because identified genes and pathways associated with ischemia were present in both TIA and stroke subjects. Because blood samples were obtained within 72 hours of TIA or stroke, differences in immune response to ischemia that may exist beyond this time remain unclear. Analysis of individual immune cells was performed based on prior studies on genes unique to each cell type. Further evaluation of individual immune cell response to ischemia in stroke and TIA is required. A clinical diagnosis of TIA has limitations in its accuracy, and this may have been introduced into the derived genes to predict ischemia in TNE. Although TIAs were selected based on criteria to make ischemia the most likely etiology, it is possible that some patients with TIA were misclassified. Patients with ischemic stroke were used to ensure the identified genes were present in patients with definitive cerebral ischemia. Future studies could follow patients with TIA and TNE over time to refine clinical diagnoses. Because short-term risk of stroke confirms that an initial event was a TIA rather than a mimic, the profile may also be valuable as a predictor of stroke risk.
In conclusion, a common peripheral response to ischemia in stroke and TIA was identified. The genes and pathways provide insight into the peripheral inflammatory response to cerebral ischemia. With further study, the common immune response may demonstrate clinical use to discriminate ischemic from nonischemic causes of TNE and thus facilitate evaluation and treatment of TIA. 
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